Top

Published in:

01-09-2013 | Original Article

TAFI gene polymorphisms in patients with cerebral venous thrombosis

Authors: Serhat Tokgoz, Ayse Gul Zamani, Hatice Gul Durakbasi-Dursun, Osman Yılmaz, Nurhan Ilhan, Sennur Demirel, Mithat Tavli, Alper Sinan

Published in: Acta Neurologica Belgica | Issue 3/2013

Abstract

Gene polymorphisms of thrombin activatable fibrinolysis inhibition (TAFI) factor have been investigated in various studies in terms of etiology (recurrence) and treatment (fibrinolytic effect) of thrombus formation. Cerebral venous thrombosis (CVT) is a life-threatening disease observed in young persons. Fifty-nine patients with CVT and 100 healthy control subjects were enrolled in the case/control study. The association between TAFI gene polymorphisms −438G>A, +505A>G and +1040C>T and cerebral venous thrombosis was investigated. It was found that frequencies of polymorphic genotype and allele were not different in patients than in control group and that they were not significant for cerebral venous thrombosis.

Bousser MG (2000) Cerebral venous thrombosis: diagnosis and management. J Neurol 247:252–258PubMedCrossRef

De Keyze K, Paemeleire K, De Clerck M, Peeters D, De Reuck JL (2004) Diabetic ketoacidosis presenting as a cerebral venous sinus thrombosis. Acta Neurol Belg 104:117–120

Gökçil Z, Odabasi Z, Vural O, Yardim M (1998) Cerebral venous thrombosis in pregnancy: the role of protein S deficiency. Acta Neurol Belg 98:36–38PubMedCrossRef

Hajjar KA, Francis CW (2006) Fibrinolysis and thrombolysis. In: Lichtman MA, Beutler E, Kipps TJ et al (eds) Williams Hematology. McGraw-Hill, New York, pp 2089–21152

Boffa MB, Wang W, Bajzar L, Nesheim ME (1998) Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 273:2127–2135PubMedCrossRef

Leurs J, Hendriks D (2005) Carboxypeptidase U (TAFla): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 94:471–487PubMed

Eaton DL, Malloy BE, Tsai SP, Henzer W, Drayna D (1991) Isolation, molecular- cloning, and partial characterization of a novel carboxypeptidase-B from human plasma. J Biol Chem 266:21833–21838PubMed

Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270:14477–14484PubMedCrossRef

Meltzer ME, Doggen CJM, de Groot PhG, Meijers JCM, Rosendaal FR, Lisman T (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94:811–818PubMedCrossRef

10.

Santamaria A, Oliver A, Borrel M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J (2003) Risk of ıschemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34:2387–2391PubMedCrossRef

11.

Montaner J, Ribó M, Monasterio J, Molina Carlos A, Alvarez-Sabín José (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34:1038–1040PubMedCrossRef

12.

Leebeek FWG, van Goor MPJ, Guimaraes AHC, Brouwers G-J, de Maat MPM, Dippel DWJ, Rijken DC (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3:2211–2218PubMedCrossRef

13.

Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA (2004) Thrombin activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103:3773–3776PubMedCrossRef

14.

van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855–2859PubMed

15.

Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J (2002) Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87:1068–1073PubMed

16.

Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, Lourenço D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA (2001) Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86:510–517PubMed

17.

Ladenvall C, Gils A, Jood K, Blomstrand C, Paul J, Declerck PJ, Jern C (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 27:955–962PubMedCrossRef

18.

Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA (2007) Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 23:41–49PubMedCrossRef

19.

Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC (2010) Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost 8:605–607PubMedCrossRef

20.

Kraft P, Schwarz T, Meijers JCM, Stoll G, Kleinschnitz C (2010) Thrombin-activatable fibrinolysis inhibitor (tafi) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS ONE 5:e11658PubMedCrossRef

21.

Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group (2005) TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 3:1503–1510PubMedCrossRef

22.

Henry M, Aubert H, Morange P, Nanni I, Alessi M, Tiret L, Juhan-Vague I (2001) Identification of polymorphisms in the promoter and the 39 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97:2053–2058PubMedCrossRef

23.

Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP (2003) Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90:92–100PubMed

24.

Juhan-Vague I, Morange PE, HIFMECH Study Group et al (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22:867–873PubMedCrossRef

25.

Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR (2006) The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 134:92–94PubMedCrossRef

26.

Akatsu H, Yamagata H, Chen Y, Miki T, Kamino K, Takeda M, Campbell W, Kondo I, Kosaka K, Yamamoto T, Okada H (2004) TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br J Haematol 127:440–447PubMedCrossRef

27.

Lichy C, Dong-Si T, Reuner K, Genius J, Rickmann H, Hampe T, Dolan T, Stoll F, Grau A (2006) Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol 253:316–320PubMedCrossRef

28.

de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW (2009) The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 7:919–927PubMedCrossRef

29.

Tassies D, Roque M, Monteagudo J, Martorell T, Sionis A, Arzomendi D, Heras M, Reverter JC (2009) Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markes of the type of acute coronary syndrome. Thromb Res 124:614–618PubMedCrossRef

30.

Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze JF (2010) Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb Haemost 103:976–983PubMedCrossRef

31.

Heylen E, Miljic P, Willemse J, Djordjevic V, Radojkovic D, Colovic M, Elezovic I, Hendriks D (2009) Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res 124:427–432PubMedCrossRef

32.

Verdu J, Marco P, Benlloch S, Lucas J (2008) Association between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease. Clin Appl Thromb Hemost 14:494PubMedCrossRef

Title: TAFI gene polymorphisms in patients with cerebral venous thrombosis
Authors: Serhat Tokgoz
Ayse Gul Zamani
Hatice Gul Durakbasi-Dursun
Osman Yılmaz
Nurhan Ilhan
Sennur Demirel
Mithat Tavli
Alper Sinan
Publication date: 01-09-2013
Publisher: Springer Milan
Published in: Acta Neurologica Belgica / Issue 3/2013
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-012-0170-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TAFI gene polymorphisms in patients with cerebral venous thrombosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Prevalence of restless legs syndrome in Ankara, Turkey: an analysis of diagnostic criteria and awareness

Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails?

Correlation between blink reflex abnormalities and magnetic resonance imaging findings in patients with multiple sclerosis

Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial

Masticatory myorhythmia following pontine hemorrhage

Erratum to: Diffusion tensor imaging (DTI) in the detection of white matter lesions in patients with mild cognitive impairment (MCI)